Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements
- PMID: 27449145
- DOI: 10.1016/j.jadohealth.2016.03.041
Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements
Abstract
Invasive meningococcal disease remains a substantial global public health burden despite being vaccine-preventable worldwide. More than one million cases are reported annually, with average fatality rates ranging from 10% to 40% depending on clinical presentation and geographic location. Survivors may suffer debilitating sequelae that reduce the quality of life for the patient and family members responsible for their care. Major financial burdens are associated with acute treatment and follow-up care, and outbreak management often places extensive financial strains on public health resources. Although the clinical and financial aspects of meningococcal disease burden are straightforward to quantify, other burdens such as lifelong cognitive deficits, psychological stress, adaptive measures for reintegration into society, familial impact, and legal costs are systematically overlooked. These and other facets of disease burden are therefore not systematically considered in cost-effectiveness analyses that public health authorities take into consideration when making decisions regarding vaccination programs. Changing the approach for measuring meningococcal disease burden is necessary to accurately understand the societal consequences of this devastating illness. In this article, the conventional and under-recognized burdens of meningococcal disease are presented and discussed.
Keywords: Disease burden; Meningococcal disease; Societal consequences.
Copyright © 2016 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The costs associated with the public health management of a cluster of meningococcal infection in England.Vaccine. 2014 Sep 29;32(43):5549-51. doi: 10.1016/j.vaccine.2014.08.044. Epub 2014 Aug 27. Vaccine. 2014. PMID: 25173479
-
Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.Pediatrics. 2005 May;115(5):1220-32. doi: 10.1542/peds.2004-2514. Pediatrics. 2005. PMID: 15867028
-
Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.Vaccine. 2007 Jul 20;25(29):5433-40. doi: 10.1016/j.vaccine.2007.04.071. Epub 2007 May 15. Vaccine. 2007. PMID: 17560695
-
Can we defeat meningococcal disease in low and middle income countries?Vaccine. 2012 May 30;30 Suppl 2:B63-6. doi: 10.1016/j.vaccine.2011.12.063. Vaccine. 2012. PMID: 22607901 Review.
-
History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.Pharmacotherapy. 2016 Aug;36(8):880-92. doi: 10.1002/phar.1790. Pharmacotherapy. 2016. PMID: 27332671 Review.
Cited by
-
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study.Epidemiol Infect. 2021 Feb 5;149:e50. doi: 10.1017/S0950268821000261. Epidemiol Infect. 2021. PMID: 33541457 Free PMC article. Clinical Trial.
-
Epidemiology of invasive meningococcal disease, Japan, 2013 to 2023.Euro Surveill. 2024 Nov;29(46):2400136. doi: 10.2807/1560-7917.ES.2024.29.46.2400136. Euro Surveill. 2024. PMID: 39544146 Free PMC article.
-
Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.Hum Vaccin Immunother. 2024 Dec 31;20(1):2406613. doi: 10.1080/21645515.2024.2406613. Epub 2024 Oct 7. Hum Vaccin Immunother. 2024. PMID: 39373020 Free PMC article.
-
What Works for Controlling Meningitis Outbreaks: A Case Study from China.Vaccines (Basel). 2023 Nov 27;11(12):1762. doi: 10.3390/vaccines11121762. Vaccines (Basel). 2023. PMID: 38140167 Free PMC article.
-
Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.BMC Public Health. 2020 Jul 14;20(1):1109. doi: 10.1186/s12889-020-09181-8. BMC Public Health. 2020. PMID: 32664872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical